Canurta Therapeutics Website
2 known investors
Canurta Therapeutics develops multi-target botanical drugs using its AI-backed PolyKye platform to identify bioactive compounds and guide compound selection, disease targeting, and formulation. Its therapies target inflammation and neurological diseases, with a lead candidate (CNR-401) aimed at Amyotrophic Lateral Sclerosis (ALS).